Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03049280 · ClinicalTrials.gov registry record · NA
Prospective, Multicenter da Vinci® SP™ Surgical System TORS Study
A NA study of Oropharyngeal Cancer, sponsored by Intuitive Surgical.
- Completed
- Registry status
- NA
- Development phase
- 33
- Enrollment target
- 3
- Study locations
NCT03049280: Completed NA study of Oropharyngeal Cancer, sponsored by Intuitive Surgical.
NCT03049280 is a NA study of Oropharyngeal Cancer that has completed, run by Intuitive Surgical. The registered enrollment target is 33 participants, below the 188-participant average among 25 other Oropharyngeal Cancer trials with a reported enrollment target (82% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03049280, a NA study of Oropharyngeal Cancer, has completed, sponsored by Intuitive Surgical.
- COMPLETED
- Registry status
- NA
- Development phase
- 33 participants
- Enrollment target
- 3
- Study locations
Study Summary
A prospective, multicenter investigation of the da Vinci® SP™ Surgical System in Transoral Robotic Surgery (TORS) procedures for malignant oropharyngeal tumors.
Primary Outcome
Performance defined as the conversion to an open approach required to complete the procedure
Conditions Studied
Interventions
- DEVICE Transoral robotic surgery
Study Locations (3)
California
- Board of Trustees of the Leland Stanford Junior University - Palo Alto
Florida
- Florida Hospital - Celebration
Pennsylvania
- Trustees of the University of Pennsylvania - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2017-04-17 |
| Est. Completion | 2017-12-26 |
| Phase | NA |
What the finished NCT03049280 record still lists
NCT03049280 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 33 participants, a relatively small participant target, below the 188-participant average among 25 other Oropharyngeal Cancer trials with a reported enrollment target (82% lower).
The record links to 1 condition, with Oropharyngeal Cancer appearing as the primary indexed condition, and to 1 intervention - of which Transoral robotic surgery is the first listed.
NCT03049280 reports a single indexed study location in California, Florida, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT03049280 about?
NCT03049280 is a clinical study titled "Prospective, Multicenter da Vinci® SP™ Surgical System TORS Study". A prospective, multicenter investigation of the da Vinci® SP™ Surgical System in Transoral Robotic Surgery (TORS) procedures for malignant oropharyngeal tumors.
What is the current status of trial NCT03049280?
This trial is currently completed. It is a NA study. The enrollment target is 33 participants. The study started on 2017-04-17. Estimated completion is 2017-12-26.
What conditions does trial NCT03049280 study?
This clinical trial studies the following conditions: Oropharyngeal Cancer.
What interventions are being tested in trial NCT03049280?
The interventions under investigation include: Transoral robotic surgery (DEVICE).
Who is sponsoring clinical trial NCT03049280?
This trial is sponsored by Intuitive Surgical, which has 40 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03049280 being conducted?
This trial has 3 study locations across California, Florida, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Oropharyngeal Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03049280's enrollment target sits among peer trials
33 19th of 25 higher than 6 of 25 other Oropharyngeal Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Oropharyngeal Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
TORS De-Intensification Protocol Version 2.0: Dose and Volume Reduction in the Neck
ACTIVE NOT RECRUITING · NA
-
Enhancing Self Care Among Oral Cancer Survivors: The Empowered Survival Trial
ACTIVE NOT RECRUITING · NA
-
A Pilot Trial of Image-Guided Adaptive Radiotherapy for Head and Neck Cancer
COMPLETED · NA
-
Biomarker Approach to Screening for the Early Detection of HPV-related Oropharyngeal Cancer (BASH OPC)
RECRUITING
-
Toripalimab in Combination With Standard Treatment for Human Papillomavirus (HPV) Positive Throat Cancer
RECRUITING · Phase 2
-
BALSTILIMAB on Viral Clearance in HPV+ Oropharyngeal Cancer Patients
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02861898 · 33 participants · Phase 1
Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma
- NCT04871607 · 33 participants · Phase 2
Yttrium-90 Labeled Anti-CD25 Monoclonal Antibody Combined With BEAM Chemotherapy Conditioning for the Treatment of Primary Refractory or Relapsed Hodgkin Lymphoma
- NCT05071937 · 33 participants · Phase 2
ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer
- NCT05168618 · 33 participants · Phase 2
Cabozantinib and Atezolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer, The AtezoCab Trial
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI